Increasing survival of ischemic tissue by targeting CD47

Circulation Research

Volumn 100, Issue 5, 2007, Pages 712-720

  Isenberg, Jeff S ^a   Romeo, Martin J ^a   Abu Asab, Mones ^a   Tsokos, Maria ^a   Oldenborg, Anna ^b   Pappan, Loretta ^b   Wink, David A ^a   Frazier, William A ^b   Roberts, David D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD47; Ischemic tissue survival; Nitric oxide; Therapeutics; Thrombospondin 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD36 ANTIGEN; CD47 ANTIGEN; IMMUNOGLOBULIN G2A ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A6.1; MONOCLONAL ANTIBODY AB 301; NITRIC OXIDE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; ISCHEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; SKIN BLOOD FLOW; SKIN FLAP; SMOOTH MUSCLE RELAXATION; TISSUE NECROSIS; TISSUE PERFUSION; TISSUE REGENERATION; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; HINDLIMB; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; ANTIGENS, CD47; DRUG DELIVERY SYSTEMS; HINDLIMB; HUMANS; ISCHEMIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION; VASODILATION;

EID: 33947732103     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000259579.35787.4e     Document Type: Article

References (40)

1. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997;39:287-324.
2. Hollenberg SM, Cunnion RE. Endothelial and vascular smooth muscle function in sepsis. J Crit Care. 1994;9:262-280.
3. Levenson JA, Simon AC, Safar ME. Vasodilatation of small and large arteries in hypertension. J Cardiovasc Pharmacol. 1985;7(suppl 2):S115-S120.
4. Segal SS. Regulation of blood flow in the microcirculation. Microcirculation. 2005;12:33-45.
5. Pohl U, De Wit C, Gloe T. Large arterioles in the control of blood flow: role of endothelium-dependent dilation. Acta Physiol Scand. 2000;168:505-510.
6. Athanasiou T, Aziz O, Al-Ruzzeh S, Philippidis P, Jones C, Purkayastha S, Casula R, Glenville B. Are wound healing disturbances and length of hospital stay reduced with minimally invasive vein harvest? A meta-analysis. Eur J Cardiothorac Surg. 2004;26:1015-1026.
7. Raghunathan A, Rapp JH, Littooy F, Santilli S, Krupski WC, Ward HB, Thottapurathu L, Moritz T, McFalls EO. Postoperative outcomes for patients undergoing elective revascularization for critical limb ischemia and intermittent claudication: a subanalysis of the Coronary Artery Revascularization Prophylaxis (CARP) trial. J Vasc Surg. 2006;43:1175-1182.
8. Nowygrod R, Egorova N, Greco G, Anderson P, Gelijns A, Moskowitz A, McKinsey J, Morrissey N, Kent KC. Trends, complications, and mortality in peripheral vascular surgery. J Vasc Surg. 2006;43:205-216.
9. Niezgoda JA, Mewissen M. The management of lower extremity wounds complicated by acute arterial insufficiency and ischemia. Ostomy Wound Manage. 2004;50(5A suppl):1-11.
10. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547-553.
11. Antignani PL. Treatment of chronic peripheral arterial disease. Curr Vasc Pharmacol. 2003;1:205-216.
12. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3:2007-2018.
13. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53:503-514.
14. Arnal JF, Dinh-Xuan AT, Pueyo M, Darblade B, Rami J. Endotheliumderived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci. 1999;55:1078-1087.
15. Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz. 1997;22:158-172.
16. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem. 2000;275:21722-21729.
17. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71:785-793.
18. Isenberg JS, Calzada MJ, Zhou L, Guo N, Lawler J, Wang XQ, Frazier WA, Roberts DD. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol. 2005;24:110-123.
19. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A. 2005;102:13147-13152.
20. Isenberg JS, Hyodo F, Matsumoto KI, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood. In press.
21. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997;138:707-717.
22. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A. 2005;102:13141-13146.
23. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem. 2006;281:26069-26080.
24. Gardai SJ, Bratton DL, Ogden CA, Henson PM. Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol. 2006;79:896-903.
25. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem. 1996;271:21-24.
26. Wang XQ, Frazier WA. The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2 beta1 integrin in vascular smooth muscle cells. Mol Biol Cell. 1998;9:865-874.
27. Guo N, Zabrenetzky VS, Chandrasekaran L, Sipes JM, Lawler J, Krutzsch HC, Roberts DD. Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. Cancer Res. 1998;58:3154-3162.
28. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274:19055-19062.
29. Gao AG, Lindberg FP, Dimitry JM, Brown EJ, Frazier WA. Thrombospondin modulates alpha v beta 3 function through integrin-associated protein. J Cell Biol. 1996;135:533-544.
30. Lindberg FP, Gresham HD, Schwarz E, Brown EJ. Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol. 1993;123:485-496.
31. Roberts DD, Cashel J, Guo N. Purification of thrombospondin from human platelets. J Tissue Cult Methods. 1994;16:217-222.
32. Paek R, Chang DS, Brevetti LS, Rollins MD, Brady S, Ursell PC, Hunt TK, Sarkar R, Messina LM. Correlation of a simple direct measurement of muscle pO(2) to a clinical ischemia index and histology in a rat model of chronic severe hindlimb ischemia. J Vasc Surg. 2002;36:172-179.
33. Bonheur JA, Albadawi H, Patton GM, Watkins MT. A noninvasive murine model of hindlimbs ischemia-reperfusion injury. J Surg Res. 2004;116:55-63.
34. Annis DS, Murphy-Ullrich JE, Mosher DF. Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost. 2006;4:459-468.
35. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41-48.
36. Oldenborg PA. Role of CD47 in erythroid cells and in autoimmunity. Leuk Lymphoma. 2004;45:1319-1327.
37. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11:130-135.
38. Grimbert P, Bouguermouh S, Baba N, Nakajima T, Allakhverdi Z, Braun D, Saito H, Rubio M, Delespesse G, Sarfati M. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25-T cells in response to inflammation. J Immunol. 2006;177:3534-3541.
39. Simons M. Angiogenesis: where do we stand now? Circulation. 2005; 111:1556-1566.
40. Chen CH, Walterscheid JP. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ Res. 2006;99:787-789.